Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Melanoma: early-phase trial registry
32 of 92 indexed Metastatic Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #148 of 28,707 conditions by registered trial count.
92 US clinical trials · 32 currently recruiting · #148 of 28,707 conditions by registered trial count
Metastatic Melanoma: 92 US clinical trials tracked, 32 recruiting.
Metastatic Melanoma is the subject of 92 registered US clinical trials on ClinicalTrials.gov, 32 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 82 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 16 of these trials.
Enrollment posture brief
Registry condition metastatic-melanoma
OPEN 32 | RECR 35% | LATE 4 | EARLY 82 | RANK #148 | SPON 16
Volume-matched condition peers
Nearest open-share peer: Invasive Breast Carcinoma (35% recruiting · 46 trials)
Metastatic Melanoma lists 32 open slots (35% of 92 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Melanoma is recruiting below its size-band peers.
32 of 92 indexed trials (34.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Melanoma research.
M.D. Anderson Cancer Center accounts for 16 of 92 trials (17.4%). 54 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Melanoma trials plan to enrol fewer than 100 people.
Median target enrolment is 37 among the 92 trials that report a genuine target (sentinel values excluded). 72 of those (78.3%) plan for fewer than 100 participants.
-
Metastatic Melanoma research is mostly interventional.
88 interventional and 4 observational studies make up this index (95.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
92 total, page 2 of 2
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
NCT03175432
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
M.D. Anderson Cancer Center
NCT03131908
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT02816021
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT05470283
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Mayo Clinic
NCT03021460
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
National Cancer Institute (NCI)
NCT01364051
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
Megan Daly, MD
NCT03474497
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
National Cancer Institute (NCI)
NCT02581930
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05628883
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
National Cancer Institute (NCI)
NCT04557956
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Massachusetts General Hospital
NCT03149029
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
NCT02650986
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
NCT04616248
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
National Cancer Institute (NCI)
NCT03816332
A Study of LN-144 in People With Metastatic Melanoma to the Brain
Memorial Sloan Kettering Cancer Center
NCT05640193
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
NCT05341349
Long-term Data Collection for Subjects in MDX-010 Studies
Bristol-Myers Squibb
NCT00928031
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
NCT02304458
Phase II Trial of Allovectin-7® for Metastatic Melanoma
Vical
NCT00044356
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Incyte Corporation
NCT03679767
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma
Eisai
NCT00121680
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma
Eisai
NCT01335009
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
SCRI Development Innovations
NCT01014351
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
John P. Fruehauf
NCT00256282
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
Craig L Slingluff, Jr
NCT02126579
RFT-5-dgA in Patients With Metastatic Melanoma
University of Texas Southwestern Medical Center
NCT00314093
Dose Escalation Study of MLN4924 in Adults With Melanoma
Millennium Pharmaceuticals
NCT01011530
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
Ludwig Institute for Cancer Research
NCT00679289
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Rahul Aggarwal
NCT03590054
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Cancer Institute (NCI)
NCT01993719
The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma
Beth Israel Deaconess Medical Center
NCT00626860
Melanoma Biomarker Study
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00348088
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
Northwestern University
NCT00301067
Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma
University of Chicago
NCT00203879
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
NCT02500576
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Walter J. Storkus
NCT01876212
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
F. Stephen Hodi, MD
NCT02141542
Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention
Parker Institute for Cancer Immunotherapy
NCT03817125
Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Scott Pruitt
NCT00672542
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
NCT01807182
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
M.D. Anderson Cancer Center
NCT01904123
Radiation and Combination Immunotherapy for Melanoma
Masonic Cancer Center, University of Minnesota
NCT03850691
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 46 |
| Phase 2 | 36 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Melanoma page
92 registered trials, 32 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 32 Metastatic Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Metastatic Melanoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Melanoma condition card totals 92 registered trials; most-linked intervention Pembrolizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.